Complex hematological tests aid in establishing hematologic diagnoses, but can be quite costly. We hypothesized that certain diagnostic tests (specifically JAK2 at $175/test, BCR-ABL at $163/test, and flow cytometry at $275/test) that were being ordered without input from a hematologist were generally not indicated and expensive. We reviewed all of these tests sent between September 2013 and September 2015. 20/55 or 36% of JAK2 mutations, 19/37 or 51% of BCR-ABL mutations, and 47/74 or 63% of flow cytometry were completed without hematology input, primarily via primary care (72/86 or 84%). Tests that were ordered or recommended by hematology were excluded from the subsequent cost analysis. In total $19,500 was spent (without hematology input). One hematologist then reviewed the charts on every test that had been ordered not by hematology to determine if the test was clinically appropriate. 12/20 or 60% of JAK2 mutations, 19/19 or 100% of BCR mutations, and 44/47 or 94% of flow cytometry evaluations were felt to be unnecessary. Thus $17,300 of the $19,500 could have been saved had there been hematology input at the outset. This would have amounted to 86 e-consults over 2 years, which would be 1.2 extra consults/week; these consults generally take under 10 minutes, so less than 2 minutes/day. This all translates to ~$1,075 over 2 years of a hematologist’s salary, clearly more cost-effective than permitting everyone to be able to order these tests. We should consider recommending hematology input prior to allowing these tests (and perhaps other costly unusual hematology investigations) to be sent out, perhaps via a pop-up suggestion for a hematology e-consult when ordered; the e-consult would also be a tool to educate other providers on the appropriate use of these tests and may ultimately lead to a decrease in the ordering of these e-consults.
Conference Coverage
The Buck Stops Here: Rational Oversight for Hematologic Testing
Abstract 24: 2016 AVAHO Meeting
Fed Pract. 2016 September;33 (supp 8):27S
Recommended Reading
Clinical Topics
-
Study of beliefs about what causes cancer sparks debate -
Tips on Better Patients Communication Publish date: October 26, 2022 -
VA Center Dramatically Shrinks Wait Times for Bone Marrow Biopsies Publish date: October 19, 2022 -
In VA Oncology, Discussion Groups Are Transforming the Workplace Publish date: October 19, 2022 -
Burnout Is Rampant, But Oncologists Can Turn the Tide Publish date: October 10, 2022
Digital Edition
-
Cancer Data Trends 2023 Publish date: July 5, 2023 -
Cancer Data Trends 2022 Publish date: March 30, 2022 -
AVAHO 2021 Meeting Posters and Abstracts Publish date: September 22, 2021 -
Advances in Hematology and Oncology Publish date: September 3, 2021 -
Advances in Hematology and Oncology Publish date: May 20, 2021
Multimedia
-
Freefall: How Skydiving Is Like Cancer Surgery Publish date: June 1, 2021 -
A Pivotal Moment in Cancer Surgery, Captured on Film Publish date: April 30, 2021 -
Laparoscopic surgery survival outcomes on par with open approach in colorectal liver metastases Publish date: June 3, 2019
Conference Coverage
-
Registered Dieticians Sparse in VA Cancer Care Publish date: November 11, 2024 -
Study Finds Elevated Skin Cancer Risk Among US Veterans Publish date: October 28, 2024 -
Which Medication Is Best? VA Genetic Tests May Have the Answer Publish date: October 4, 2024 -
IMRT vs Proton Therapy for Early Prostate Cancer? Publish date: October 3, 2024 -
Head and Neck Cancer: Should Patients Get PEG Access Prior to Therapy? VA pilot study could help clinicians make better-informed decisions to head off malnutrition Publish date: September 27, 2024 -
Transgender Women and Prostate Cancer: It’s Complicated Publish date: September 23, 2024 -
Changes in Age-Related Mortality in Malignant Melanoma From 1999- 2022: A CDC Wonder Study -
Geographical Trends in Malignant Melanoma from 1999-2022: A CDC Wonder Study -
Implementation of an Intervention to Improve Efficiency and Accuracy of Data Entry into the Veterans Affairs Central Cancer Registry at the Lexington VA Healthcare System -
A Phase II Study With Androgen Deprivation Therapy and Up-Front Radiotherapy in High-Intermediate and High-Risk Prostate Cancer With Stereotactic Body Radiation Therapy to Pelvic Nodes and Concomitant Prostate Boost by Simultaneous Integrated Boost
CLL incidence by race and location
Question 1 of 5